Skip to main content

Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • (3rd July, 2014); Four new vaccines are introduced as part of India’s Universal Immunization Programme (UIP), announced by Shri Narendra Modi, Prime Minister of India. Vaccines against rotavirus, rubella and polio (injectable) will collectively expedite India’s progress on meeting the Millennium Development Goal 4 targets to reduce child mortality by two-thirds by the year 2015 and meet global polio eradication targets. In addition, an adult vaccine against Japanese encephalitis will be introduced in districts with high levels of the disease.

  • Health Minister discussed Indian health system & scenarios at Centre for Disease Control and Prevention, Atlanta

    (30th June, 2014); Union Health Minister Dr. Harsh Vardhan held a four hour long meeting with top experts at the world famous Centre for Disease Control and Prevention (CDC) at Atlanta on 28th June.

  • BGS Global Hospitals Performs the 1st Dual Organ Transplantation in Karnataka

    (Business Wire India; 30th June, 2014); BGS Global Hospitals, Super Specialty Tertiary Care,  on the eve of doctor’s day, organized a press conference on the 1st successful Combined Dual Organ (Liver and Kidney) Transplantation procedure in Karnataka.

  • Type 2 Diabetes: Jardiance® (empagliflozin) as an add-on therapy significantly reduced blood glucose and body weight in two newly presented Phase III trials

    (20th June, 2014); Boehringer Ingelheim and Eli Lilly and Company presented results of two Phase III clinical trials studying the efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in adults with Type 2 Diabetes (T2D) at the American Diabetes Association's 74th Scientific Sessions®. Results showed that empagliflozin in combination with certain other diabetes therapies reduced blood glucose, body weight and blood pressure.

  • (Business Wire India; 20th June, 2014); Boehringer Ingelheim today announces a new study of Pradaxa® (dabigatran etexilate) in patients with atrial fibrillation (AF). The RE-CIRCUIT™ study will investigate the safety and efficacy of uninterrupted anticoagulant treatment with Pradaxa® in patients with AF who undergo ablation. Results of the study are expected in 2016.

    [adsense:336x280:8701650588]

  • (Business Wire India; 19th June, 2014); Wincere Inc., a visionary full service contract research organization and life sciences  focused consulting company today organized a panel discussion in association with International CMEs Oncology on “Precision Medicine – Trends in Oncology”, promising to revolutionize cancer research.

  • (Business Wire India; 16th June, 2014); Acute myeloid leukaemia (AML) is a devastating form of blood cancer that mainly affects people over 60 years old. For older patients who receive chemotherapy, the median survival is less than a year. Even though AML is considered rare, it accounts for around 18,860 new cases and 10,000 deaths in the US each year and is the most frequent cause of leukaemia-related deaths.

  • (Business Wire India; 5th June, 2014); A new report by the Advanced Medical Technology Association (AdvaMed) demonstrates the lack of awareness among consumers about medical devices.
    The findings of a survey of 1300 Indians from across 17 states conducted by AdvaMed – an association of medical device manufacturers leading the effort to provide medical technology to the world – reveals that although an overwhelming 72% of respondents use medical devices, 89% say that they do not know enough about them.

Subscribe to Pharma News